Quetiapine for the treatment of behavioural and psychological symptoms of dementia (bpsd): A metaanalysis of randomised placebo-controlled trials

New Zealand Medical Journal

Volumn 124, Issue 1336, 2011, Pages

  Cheung, Gary ^a   Stapelberg, Janli ^b  

^a AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^b Botany Town Medical Centre   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

QUETIAPINE;

AGED; ARTICLE; AUSTRALIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MALE; MEDLINE; META ANALYSIS; NETHERLANDS; OUTCOME ASSESSMENT; PSYCINFO; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; UNITED STATES;

EID: 79958289014     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Alzheimers New Zealand Incorporated. 2008. Dementia Economic Impact Report. Wellington.
2. Access Economics. 2005. Dementia estimates and projections: Australian States and Territories-Report by Access Economics Pty Limited for Alzheimer's Australia. Canberra.
3. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc. 1996 Sep;44(9):1078-81.
4. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000 May;157(5):708-14.
5. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry. 2000 Jul;15 Suppl 1:S2-4.
6. Rainer M, Haushofer M, Pfolz H, et al. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. Eur Psychiatry. 2007 Sep;22(6):395-403. Epub 2007 May 4.
7. Rocca P, Marino F, Montemagni C, et al. Risperidone, olanzapine and quetiapine in the treatment of behavioural and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study. Psychiatry Clin Neurosci. 2007 Dec;61(6):622-9.
8. Onor ML, Saina M, Aguglia E. Efficacy and tolerability of quetiapine in the treatment of behavioural and psychological symptoms of dementia. Am J Alzheimers Dis Other Demen. 2006 Dec-2007 Jan;21(6):448-53.
9. Fujikawa T, Takahashi T, Kinoshita A, et al. Quetiapine treatment for behavioural and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology. 2004;49(4):201-4.
10. Scharre DW, Chang SI. Cognitive and behavioural effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2002 Apr-Jun;16(2):128-30.
11. Ballard C, Corbett A, Chitramohan R, Aarsland D. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Curr Opin Psychiatry. 2009 Nov;22(6):532-40. Review.
12. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006 Mar;14(3):191-210.
13. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006 Jun;7(6):492-500.
14. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003476. Review.
15. Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioural symptoms of dementia. J Am Geriatr Soc. 2006 Feb;54(2):354-61.
16. Yury CA, Fisher JE. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom. 2007;76(4):213-8.
17. Faculty of Psychiatry of Old Age (New Zealand), the Royal Australian and New Zealand College of Psychiatrists (New Zealand Branch). The use of antipsychotics in residential aged care. 2008. Wellington.
18. Bishara D, Taylor D, Howard RJ, Abdel-Tawab R. Expert opinion on the management of behavioural and psychological symptoms of dementia (BPSD) and investigation into prescribing practices in the UK. Int J Geriatr Psychiatry. 2009 Sep;24(9):944-54.
19. Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioural disturbances. http://www.fda.gov/cder/drug/advisory/antipsychotics.htm
20. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308-14.
21. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S22-32.
22. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005 Apr 16;330(7496):874. Epub 2005 Feb 18.
23. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006 Oct 12;355(15):1525-38.
24. Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006 Sep;14(9):767-76. Epub 2006 Aug 11.
25. Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007 Apr 24;68(17):1356-63.
26. Zhong KX, Tariot PN, Mintzer J, et al. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007 Feb;4(1):81-93.
27. Paleacu D, Barak Y, Mirecky I, Mazeh D. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry. 2008 Apr;23(4):393-400.
28. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioural changes in Alzheimer's disease. Neurology. 1996 Jan;46(1):130-5.
29. On behavioural symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol. 1996 Jan;9(1):1-6.
30. Wang PS, Schneeweiss PHS, Avorn J, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med. 2005 Dec;353(22):2335-2341.
31. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005 Oct 19;294(15):1934-43.
32. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009 Aug 22;374(9690):620-7.
33. Chan WC, Lam LC, Choy CN, et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16:1156-1162.
34. De Deyn P, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioural symptoms of dementia. Neurology 1999;53:946-955.
35. Suh GH, Son HG, Ju YS, et al. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioural disturbances. Am J Geriatr Psychiatry 2004;12:509-516.
36. Faculty of Psychiatry of Old Age, the Royal Australian and New Zealand College of Psychiatrists. Practice Guideline: Antipsychotic medications as a treatment of behavioural and psychological symptoms in dementia. 2006. Melbourne.
37. Campbell N, Ayub A, Boustani MA, et al. Impact of cholesterase inhibitors on behavioural and psychological symptoms of Alzheimer's disease: a meta-analysis. Clin Interv Aging. 2008;3(4):719-28.
38. Pollock BG, Mulsant BH, Rossen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioural disturbances in hospitalized, demented patients. Am J Psychiatry. 2002 Mar;159(3):460-5.
39. Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioural and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007 Nov;15(11):942-52. Epub 2007 Sep 10.
40. Siddique H, Hynan LS, Weiner MF. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. J Clin Psychiatry. 2009 Jun;70(6):915-8. Epub 2009 May 5.
41. Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008;33:957-970.
42. Christensen DB, Benfield WR. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. J Am Geriatr Soc 1998 May;46(5):620-625.
43. Coccaro EF, Kramer E, Zemishlany Z, et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990;147:1640-1645.
44. Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:327-32. Epub 2009 Jun 10.
45. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005 Aug;20(8):958-63.
46. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labelled study of 3 months' duration. Mov Disord. 2007 Feb 15;22(3):313-8.
47. Low-dose clozapine for the treatment of drug-induced psychosis in parkinson's disease. The Parkinson Study Group. N Engl J Med. 1999 Mar 11;340(10):757-63.
48. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004 May;75(5):689-95.
49. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000 Dec 16;356(9247):2031-6.